An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 22
- 主要终点
- Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV
研究概览
简要总结
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related haploidentical donor. All patients are planned to receive two ATIR101 doses of 2×10E6 viable T-cells/kg, unless the second dose is reduced or halted for safety reasons.
详细描述
Study CR-AIR-008 is an exploratory, open-label, multicenter study. After signing informed consent, patients will receive a hematopoietic stem cell transplantation (HSCT) from a related, haploidentical donor, followed by a first ATIR101 infusion at a dose of 2×10E6 viable T-cells/kg between 28 and 32 days after the HSCT. Patients will receive a second ATIR101 infusion at a dose of 2×10E6 viable T-cells/kg between 70 and 74 days after the HSCT. To evaluate safety of the second dose administration, the first 6 patients treated will be evaluated for the occurrence of dose limiting toxicity (DLT), defined as acute GvHD grade III/IV within 120 days post HSCT (or within 42 days after the second ATIR101 infusion in case of prior dose delays). If within the first 6 patients no DLT is observed, treatment of the remaining 9 patients will continue with two ATIR101 doses of 2×10E6 viable T cells/kg. If within the first 6 patients at least 2 patients show DLT, the second ATIR101 infusion will be adjusted to a dose of 1×10E6 viable T cells/kg. If in one of the next 3 patients treated at this lower dose again DLT is observed, the second ATIR101 infusion will be halted and the remaining patients will be given only a single dose of ATIR101.
All patients treated with ATIR101 will be followed up until 12 months after the HSCT. Assessments will be performed at weekly visits from the day of the first ATIR101 infusion (Week 4) until 6 weeks after the second ATIR101 infusion (Week 16), at monthly visits from 4 until 6 months after the HSCT, and every 3 months from 6 until 12 months after the HSCT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any of the following hematologic malignancies:
- •Acute myeloid leukemia (AML) in first remission with high-risk features or in second or higher remission
- •Acute lymphoblastic leukemia (ALL) in first remission with high-risk features or in second or higher remission
- •Myelodysplastic syndrome (MDS): transfusion-dependent, or intermediate or higher IPSS-R risk group
- •Karnofsky performance status ≥ 70%
- •Eligible for haploidentical stem cell transplantation according to the investigator
- •Male or female, age ≥ 18 years and ≤ 65 years
排除标准
- •Availability of a fully matched related or unrelated donor following a donor search
- •Diffusing capacity for carbon monoxide (DLCO) < 50% predicted
- •Left ventricular ejection fraction < 50% (evaluated by echocardiogram or MUGA)
- •AST > 2.5 x ULN (CTCAE grade 2)
- •Bilirubin > 1.5 x ULN (CTCAE grade 2)
- •Creatinine clearance < 50 mL/min (calculated or measured)
- •Positive HIV test
- •Positive pregnancy test (women of childbearing age only)
- •Prior allogeneic HSCT
- •Estimated probability of surviving less than 3 months
- •Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
- •Known presence of HLA antibodies against the non-shared donor haplotype
- •Any other condition which, in the opinion of the investigator, makes the patient ineligible for the study
- •Inclusion Criteria Donor:
- •Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or -DR loci of the unshared haplotype
- •Male or female, age ≥ 16 and ≤ 75 years (If applicable, local legal requirements for donors under the age of 18 will be followed)
- •Eligible for donations of human blood and blood components according to local requirements and regulations
- •Eligible for donation according to the transplantation center
- •Exclusion Criteria Donor:
- •Positive pregnancy test or nursing (women of childbearing age only)
- •Positive viral test for HIV-1, HIV-2, HBV, HCV, Treponema pallidum, HTLV 1 (if tested), HTLV-2 (if tested), or WNV (if tested)
结局指标
主要结局
Incidence of Acute Graft Versus Host Disease (GVHD) Grade III/IV
时间窗: 180 days post HSCT
次要结局
- Relapse-related Mortality (RRM)(12 months post HSCT)
- Percentage of Participants Who Achieved T-Cell Reconstitution at 6 and 12 Months Post HSCT(6 and 12 months post HSCT)
- Viral, Fungal, and Bacterial Infections(From 6 months to 1 year after HSCT)
- Transplant-related Mortality (TRM)(12 months post HSCT)
- Overall Survival (OS)(12 months post HSCT)
- Incidence and Severity of Acute and Chronic GVHD(Between 6 and 12 months after HSCT)
- Progression-free Survival (PFS)(12 months post HSCT)
- GVHD-free, Relapse-free Survival (GRFS)(12 months post HSCT)